Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in a live moderated fireside chat on Tuesday, May 2nd at 2:00 PM ET

ISELIN, N.J., April 27, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer and Glen Olsheim as Executive Director, Commercial Excellence of Outlook Therapeutics will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at Nasdaq on Tuesday, May 2, 2023 at 2:00 PM ET.

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the fireside chat will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, and in anticipation of potential FDA approval in August 2023, Outlook Therapeutics and AmerisourceBergen have entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance and other services in the United States. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:
Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
OTLK@jtcir.com

Staff

Recent Posts

Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®

New collaboration delivers 50% off prescription sleep support for new customers who are struggling with…

1 hour ago

EnrollHere and SunFire Announce Strategic Partnership to Deliver Seamless, End-to-End Medicare Enrollment Technology

WILMINGTON, N.C. , June 9, 2025 /PRNewswire/ -- EnrollHere, a next-generation Medicare technology platform, and SunFire,…

1 hour ago

Chicago Faucets Hosts Public Health Webinar to Help Facilities Comply with Emerging Legionella Regulations

Spenser Johnson to Present "Navigating Evolving Water Management Regulations: Ensuring Compliance & Public Safety" Thursday,…

1 hour ago

Dr. Sameer Berry, Oshi Health Co-Founder and Chief Medical Officer, Named to Modern Healthcare’s 50 Most Influential Clinical Executives

In helping create and scale Oshi as the first nationwide virtual GI clinic, Berry has…

1 hour ago

Washington County, NY Sheriff’s Office First in the Nation to Provide Sheriff Rx™

Prescription Discount Program for County Employees in Partnership with BI2 Technologies, LLC FORT EDWARD, N.Y.,…

1 hour ago

Sage Adds AI-Powered Fall Detection and Wellness Trend Monitoring to its All-in-One Senior Care Platform

NEW YORK, June 9, 2025 /PRNewswire/ -- Sage, the first cloud-based operating system built for senior…

1 hour ago